Undifferentiated pleomorphic sarcoma (UPS) is a rare and highly aggressive malignancy that belongs to the group of soft tissue sarcomas. It usually occurs in the soft tissues of the body, such as muscle, adipose soft tissue, and fascia, but can also develop in bones and organs. This disease is characterized by a high degree of anaplasia and a variety of cellular forms, which complicates its diagnosis and treatment. UPS is most often observed in adults, especially between the ages of 50 and 70, but can also occur in younger people. Since UPS develops rapidly, the first manifestation of the disease is often the discovery of already large tumors, which emphasizes the need for early diagnosis and a comprehensive approach to treatment.
History of the disease and interesting historical facts
The history of undifferentiated pleomorphic sarcoma includes significant advances in pathology and oncology. In the 1930s, researchers began to describe tumors that defied clear classification in existing classification systems. The most notable contribution was the work of Furie in the 1960s, in which he identified a group of soft tissue sarcomas under the general name “pleomorphic sarcomas.” Since then, researchers have begun to focus on the molecular mechanisms underlying the tumor process and mutations, leading to significant discoveries in genetic markers and disease pathogenesis.
Epidemiology
Undifferentiated pleomorphic sarcoma is considered a rare disease, observed in 0.1-0.2 cases per 100,000 people per year. According to the World Health Organization, it accounts for about 5% of the total number of all malignant sarcomas. The age groups most often affected by UPS are people over 50 years old, with men suffering slightly more often than women. According to some data, the incidence among men can reach 1 case per 100,000.
Genetic predisposition to this disease
Genetic predisposition to undifferentiated pleomorphic sarcoma is a complex multifactorial process. Studies show that certain genetic mutations, such as those in the TP53, MDM2, and CDK4 genes, may be involved in the development of this disease. Mutations in the TP53 gene, which is responsible for cell cycle control and apoptosis, often correlate with a high level of anaplasia in tumor cells. In recent years, the influence of polymorphisms in other genes, such as IGF2 and FLT3, on predisposition to this sarcoma has also been considered.
Risk factors for the development of this disease
There are several known risk factors associated with the development of undifferentiated pleomorphic sarcoma:
- Age: The disease is most common in older people, especially those between the ages of 50 and 70.
- Gender: Men have a slightly higher risk of developing NPC than women.
- Prior radiation therapy: Radiation exposure may increase the risk of developing various malignancies, including NSCLC.
- Chemical agents: Certain chemicals, such as arsenic and formaldehyde, have been linked to an increased risk of developing sarcomas.
- Certain inherited syndromes: Li-Fraumeni syndrome and other inherited syndromes may increase the chance of developing NPS.
Diagnosis of this disease
Diagnosis of undifferentiated pleomorphic sarcoma requires a comprehensive approach and includes several key stages:
- Main symptoms: The first manifestations of the disease may include a painless formation in soft tissues, a rapid increase in the size of the tumor, and possible pain in the affected area.
- Laboratory tests: A complete lipid profile and inflammatory markers may help in the initial evaluation of the patient.
- Radiologic tests: Ultrasound, CT scan, and MRI may be used to determine the size of the tumor and its effect on surrounding tissue.
- Pathologic anatomy: Biopsy is the key step in establishing the morphologic diagnosis, and tumor cells typically show a high level of cellular atypia.
- Differential diagnosis: It is a good idea to differentiate NSCs from other types of sarcomas and soft tissue tumors based on morphology and molecular characteristics.
Treatment
Treatment of undifferentiated pleomorphic sarcoma is based on the extent of tumor spread and the overall clinical picture. It may include:
- General treatment: Chemotherapy and radiotherapy may be used as adjuvant therapy after surgery.
- Pharmacological treatment: In some cases, the range of use of immunotherapy or targeted therapy may be discussed depending on the molecular abnormalities.
- Surgical treatment: Surgery to remove the tumor is the standard of treatment, often requiring radical intervention to achieve complete resection.
- Other treatments: Innovative approaches such as localized chemotherapy or the use of stereotactic radiotherapy may be considered in cases of recurrence.
List of medications used to treat this disease
Some of the common drugs used in the treatment of undifferentiated pleomorphic sarcoma include:
- Doxorubicin (Adriamycin)
- Density (Dacarbazine)
- Gemcitabine (Gemcitabine)
- Paclitaxel (Paclitaxel)
- Tyrosine kinase inhibitor drugs (eg, imatinib)
Disease monitoring
Monitoring of the patient's condition includes regular follow-up examinations and radiological examinations after treatment:
- Control stages: It is recommended to carry out control 3-6 months after treatment, taking into account the nature of the intervention.
- Prognosis: The prognosis of NPC depends on the stage of the disease and the complete removal of the tumor.
- Complications: Relapses of the disease and metastasis are possible, which requires careful monitoring and, if necessary, correction of therapy.
Age-related features of the disease
Age-related features of undifferentiated pleomorphic sarcoma are manifested in differences in the manifestation and course of the disease. In young people, the disease can develop faster, while in older patients, slower tumor growth is more often observed, but with a higher risk of surgical complications.
Questions and Answers
- What are the main symptoms of undifferentiated pleomorphic sarcoma? The main symptoms include an enlarged painless tumor-like formation in the soft tissues and possible pain in the affected area.
- How is this disease diagnosed? Diagnosis is based on a combination of clinical examination, pathomorphological studies, radiological methods and multiple biopsies.
- What are the risk factors for NPS? Risk factors include age, gender, radiation history, exposure to carcinogens, and the presence of hereditary syndromes.
- How is undifferentiated pleomorphic sarcoma treated? Treatment may include surgery, chemotherapy, and radiation therapy, depending on the stage and location of the tumor.
- What is the prognosis for patients with NPS? The prognosis depends on the stage of the disease at the time of diagnosis, but, as a rule, undifferentiated pleomorphic sarcoma has a high degree of aggressiveness and requires carefully organized monitoring.
